2002        2001*    % change
                                                 (pound)m    (pound)m
--------------------------------------------------------------------------------
Antibody engineering                               53.1        35.5        +49
Asacol                                              7.6         9.8        -22
Pertactin                                          11.0         8.4        +31
Mylotarg                                            2.7         4.0        -33
Other                                               2.3         1.1       +109
                                                   ---------------------------
                                                   76.7        58.8        +30
Effect of exchange differences                       --         2.6
                                                   ---------------------------
As reported                                        76.7        61.4        +25
--------------------------------------------------------------------------------

      The productivity of Celltech's  research operations has been significantly
      enhanced  through use of the SLAM technology for rapid  generation of very
      high affinity antibodies, and the Neogenesis collaboration, which provides
      an ultra  high  throughput  screening  capability  for the small  molecule
      pipeline.  The SLAM  technology,  acquired  from Abgenix in 2001, is being
      intensively exploited in novel target validation,  and also in therapeutic
      antibody  construction,  within  Celltech's  Seattle  and Slough  Research
      Centres. Celltech has further developed this technology, and believes that
      it now affords  significant  advantages over current methods for selecting
      high  affinity  human or near-human  antibodies.  These  technologies  are
      expected to  contribute to a sustained  increase in  Celltech's  discovery
      output in future years...